Gilmer T M, Annab L A, Oshimura M, Barrett J C
Mol Cell Biol. 1985 Jul;5(7):1707-13. doi: 10.1128/mcb.5.7.1707-1713.1985.
The ability of cloned Rous sarcoma virus (RSV) DNA encoding the v-src oncogene to neoplastically transform normal, diploid Syrian hamster embryo (SHE) cells was examined. Transfection of RSV DNA into early passage SHE cells resulted in a low but significant number of tumors when treated cells were injected into nude mice. Tumors formed with a low frequency (two tumors out of ten sites injected) and only after a long latency period (14 weeks). In contrast to the normal SHE cells, several different carcinogen-induced preneoplastic immortal SHE cell lines were highly susceptible to transformation by the v-src oncogene to the neoplastic phenotype. Tumors formed with high efficiency and a short latency period (less than 3 weeks). Further studies were performed to determine the basis for the inefficient transformation of the normal SHE cells. NeoR clones isolated after cotransfection of SHE cells with pSV2-neo and RSV DNAs were neither morphologically altered nor immortal and did not contain detectable levels of the v-src gene product. These results suggest that neoplastic transformation by v-src DNA in the normal cells is initially suppressed. However, cells from a v-src-induced tumor expressed v-src RNA, and antibody to v-src protein precipitated from the tumor cells a 60,000-molecular-weight protein which displayed protein kinase activity. Karyotypic analyses confirmed that the tumor was derived from Syrian hamster cells and suggested that it was clonal in nature. These results indicate that the v-src oncogene was primarily responsible for neoplastic transformation of SHE cells. In contrast to the results with the v-src oncogene, our previous studies showed that v-Ha-ras oncogene alone is unable to induce neoplastic transformation of SHE cells. Furthermore, the v-myc oncogene was able to compliment v-Ha-ras to neoplastically transform SHE cells, while cotransfection with v-src plus v-myc did not increase the incidence of tumors.
对编码v-src癌基因的克隆劳氏肉瘤病毒(RSV)DNA使正常二倍体叙利亚仓鼠胚胎(SHE)细胞发生肿瘤转化的能力进行了检测。将RSV DNA转染到早期传代的SHE细胞中,当将处理后的细胞注射到裸鼠体内时,会产生少量但数量可观的肿瘤。肿瘤形成频率较低(十个注射部位中有两个肿瘤),且只有在很长的潜伏期(14周)后才会出现。与正常SHE细胞不同,几种不同的致癌物诱导的癌前永生SHE细胞系对v-src癌基因转化为肿瘤表型高度敏感。肿瘤高效形成且潜伏期短(不到3周)。进行了进一步研究以确定正常SHE细胞转化效率低下的原因。用pSV2-neo和RSV DNA共转染SHE细胞后分离得到的NeoR克隆在形态上既无改变也未永生,且未检测到可检测水平的v-src基因产物。这些结果表明,正常细胞中v-src DNA引起的肿瘤转化最初受到抑制。然而,来自v-src诱导肿瘤的细胞表达v-src RNA,并且从肿瘤细胞中沉淀出的v-src蛋白抗体沉淀出一种具有蛋白激酶活性的60,000分子量的蛋白质。核型分析证实该肿瘤源自叙利亚仓鼠细胞,并表明其本质上是克隆性的。这些结果表明,v-src癌基因是SHE细胞肿瘤转化的主要原因。与v-src癌基因的结果相反,我们之前的研究表明,单独的v-Ha-ras癌基因无法诱导SHE细胞发生肿瘤转化。此外,v-myc癌基因能够与v-Ha-ras协同作用使SHE细胞发生肿瘤转化,而v-src与v-myc共转染并未增加肿瘤发生率。